Bio-Rad's Q4 Sales Increase 8 Percent | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Bio-Rad Laboratories reported after the close of the market Thursday that its fourth-quarter revenues increased 8 percent, and 10 percent on a currency-neutral basis, led by a double-digit gain for its Clinical Diagnostics segment.

The Hercules, Calif.-based firm brought in total revenues of $533.7 million for the three-month period ended Dec. 31, compared to $495.1 million for Q4 2009. It easily beat analysts' consensus estimate of $514.5 million for the quarter.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: characterization of functional genomic features in breast cancer cell lines, epigenetic pattern linked to obesity, and more.

President Obama's proposed budget for fiscal year 2017 includes an increase for NIH, but seeks some of it as mandatory funding.

Sure Genomics begins to offer direct-to-consumer genome sequencing for $2,500.

Intelligence officials in the US have added gene editing to a list of weapons of mass destruction.